Proteomics profiling of extracellular vesicle for identification of potential biomarkers in Alzheimer's disease: A comprehensive review
Ageing Research Reviews,
Год журнала:
2024,
Номер
99, С. 102359 - 102359
Опубликована: Май 29, 2024
Язык: Английский
Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(19), С. 10570 - 10570
Опубликована: Сен. 30, 2024
Glioblastoma
(GBM)
is
the
most
common
malignant
primary
brain
tumor
in
adults.
Despite
an
established
standard
of
care
including
surgical
resection,
radiation
therapy,
and
chemotherapy,
GBM
unfortunately
associated
with
a
dismal
prognosis.
Therefore,
researchers
are
extensively
evaluating
avenues
to
expand
therapy
improve
outcomes
patients
GBM.
In
this
review,
we
provide
broad
overview
novel
therapies
that
have
recently
completed
or
actively
undergoing
study
clinical
trials.
These
across
medical,
surgical,
We
additionally
review
methods
for
improving
trial
design
Язык: Английский
GBM immunotherapy: Exploring molecular and clinical frontiers
Life Sciences,
Год журнала:
2024,
Номер
356, С. 123018 - 123018
Опубликована: Авг. 28, 2024
Язык: Английский
Leptomeningeal Disease: Current Approaches and Future Directions
Current Neurology and Neuroscience Reports,
Год журнала:
2025,
Номер
25(1)
Опубликована: Март 18, 2025
Abstract
Purpose
of
Review
Leptomeningeal
disease
(LMD),
or
spread
cancer
cells
into
the
pia
and
arachnoid
membranes
encasing
brain
spinal
cord,
is
associated
with
high
symptom
burden
poor
survival
at
2
to
5
months.
Conventional
treatments
including
photon-based
radiation
therapy,
systemic
chemotherapy,
intrathecal
chemotherapy
demonstrate
limited
efficacy.
Despite
significant
successes
for
a
range
solid
tumors,
immunotherapy
has
not
yet
demonstrated
efficacy
in
management
LMD.
Advances
understanding
LMD
pathophysiology,
improved
diagnostics,
novel
therapeutics
are
shifting
this
paradigm.
In
article,
we
review
diagnostic
treatment
challenges
Recent
Findings
We
discuss
use
cerebrospinal
fluid
(CSF)
analysis
techniques
such
as
circulating
tumor
cell
CSF
cell-free
DNA
assessment
overcome
limitations
conventional
modalities.
then
advances
clinical
trial
data
demonstrating
proton
craniospinal
treat
entire
neuroaxis.
emerging
regarding
targeted
conferring
durable
benefit.
Summary
Novel
combinatorial
approaches
will
likely
further
improve
outcomes
patients
Язык: Английский
Proteomics Studies on Extracellular Vesicles Derived from Glioblastoma: Where Do We Stand?
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(18), С. 9778 - 9778
Опубликована: Сен. 10, 2024
Like
most
tumors,
glioblastoma
multiforme
(GBM),
the
deadliest
brain
tumor
in
human
adulthood,
releases
extracellular
vesicles
(EVs).
Their
content,
reflecting
that
of
origin,
can
be
donated
to
nearby
and
distant
cells
which,
by
acquiring
it,
become
more
aggressive.
Therefore,
study
EV-transported
molecules
has
very
important.
Particular
attention
been
paid
EV
proteins
uncover
new
GBM
biomarkers
potential
druggable
targets.
Proteomic
studies
have
mainly
performed
“bottom-up”
mass
spectrometry
(MS)
analysis
EVs
isolated
different
procedures
from
conditioned
media
cultured
biological
fluids
patients.
Although
a
great
number
dysregulated
identified,
translation
these
findings
into
clinics
remains
elusive,
probably
due
multiple
factors,
including
lack
standardized
for
isolation/characterization
their
proteome.
Thus,
it
is
time
change
research
strategies
adopting,
addition
harmonized
selection
techniques,
MS
methods
aimed
at
identifying
selected
tumoral
protein
mutations
and/or
isoforms
post-translational
modifications,
which
deeply
influence
behavior.
Hopefully,
data
integrated
with
those
other
“omics”
disciplines
will
lead
discovery
pathways
novel
therapies.
Язык: Английский
Application of Circulating Tumor DNA in the Auxiliary Diagnosis and Prognosis Prediction of Glioma
Cellular and Molecular Neurobiology,
Год журнала:
2024,
Номер
45(1)
Опубликована: Дек. 18, 2024
Glioma
is
the
most
common
primary
malignant
brain
tumor.
Despite
significant
advances
in
past
decade
understanding
molecular
pathogenesis
of
this
tumor
and
exploring
therapeutic
strategies,
prognosis
patients
with
glioma
remains
poor.
Accurate
diagnosis
very
important
for
treatment
prognosis.
Although
gold-standard
method
prediction
tissue
biopsy,
it
still
has
many
limitations.
Liquid
biopsy
can
provide
information
on
auxiliary
gliomas.
In
review,
we
summarized
application
cell-free
DNA
(cfDNA)
circulating
(ctDNA)
glioma.
The
methods
used
to
detect
ctDNA
gliomas
using
samples
including
blood
cerebrospinal
fluid
(CSF)
detection
techniques
ctDNA,
droplet
digital
PCR
(ddPCR)
next-generation
sequencing
(NGS),
were
discussed.
Detection
from
plasma
tumors
challenging
because
blood–brain
barrier
(BBB).
CSF
been
proposed
as
a
medium
analysis
tumors,
mutation
was
less
sensitive
than
sequencing.
Moreover,
ongoing
relevant
clinical
studies
summarized.
Finally,
discussed
challenges,
future
directions
Язык: Английский